Literature DB >> 6301369

Ceftriaxone pharmacokinetics in newborn infants.

G H McCracken, J D Siegel, N Threlkeld, M Thomas.   

Abstract

Ceftriaxone pharmacokinetics were determined in 40 newborn infants who were 1 to 45 days of age. Mean peak plasma concentrations of 136 to 173 micrograms/ml were observed at the completion of a 15-min intravenous infusion of 50 mg of ceftriaxone per kg. Mean half-life values were 5.2 to 8.4 h, and mean plasma clearances were 0.7 to 1.8 ml/min. Rectal swab cultures from 14 of 16 infants had either reduced numbers of aerobic and anaerobic bacteria or no growth during therapy. A once-daily dosage schedule is suggested for ceftriaxone therapy in newborn infants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301369      PMCID: PMC186052          DOI: 10.1128/AAC.23.2.341

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.

Authors:  M Del Rio; G H McCracken; J D Nelson; D Chrane; S Shelton
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

3.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

4.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

5.  Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis.

Authors:  Y Sakata; A Boccazzi; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

6.  Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

  6 in total
  13 in total

Review 1.  A perspective on new beta-lactam antibiotics in pediatric patients.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1984-05

2.  The potential uses of ceftriaxone.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

5.  Evaluation of a potential clinical interaction between ceftriaxone and calcium.

Authors:  Emily Steadman; Dennis W Raisch; Charles L Bennett; John S Esterly; Tischa Becker; Michael Postelnick; June M McKoy; Steve Trifilio; Paul R Yarnold; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children.

Authors:  E Martin
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

8.  Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis.

Authors:  J P Bryan; H Rocha; H R da Silva; A Taveres; M A Sande; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

9.  Pharmacokinetics and safety of ceftriaxone in the neonate.

Authors:  A Mulhall; J de Louvois; J James
Journal:  Eur J Pediatr       Date:  1985-11       Impact factor: 3.183

Review 10.  Pharmacokinetics of cephalosporins in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.